Concepedia

Author

M E van der Burg

Rotterdam University of Applied Sciences

Also Known As

A.F. Fuller, M E van der Burg, M. E. Van der Burg, M. E. van der Burg, M.E van der Burg, M.E. van der Burg, M.E.L. van der Burg

21

Publications

1.8K

Citations

15

H-Index

40

Concepts

All Affiliations

Rotterdam University of Applied SciencesErasmus MCMount Vernon Cancer CentreErasmus MC Cancer InstituteUniversity of Amsterdam
ME

About

M E van der Burg is an author at Rotterdam University of Applied Sciences specializing in oncology, medicine, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

10

10

871

2

Health Sciences

4

4

124

3

Social Sciences

1

1

32

4

Neurology

1

1

32

5

Neuroscience

1

1

32

M E van der Burg

×

15

Publications

1.7K

Citations

15

H-Index

YearCitations

European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.

Elizabeth A. Eisenhauer, W.W. ten Bokkel Huinink, Kenneth D. Swenerton,

Journal of Clinical Oncology

1994

640

Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma.

J.P. Neijt, W W ten Bokkel Huinink, M E van der Burg,

Journal of Clinical Oncology

1987

312

A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Cooperative Group.

P J van Diest, Peter A. van Dam, S.C. Henzen‐Logmans,

Journal of Clinical Pathology

1997

199

A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials)

Gordon Rustin, M E van der Burg

Journal of Clinical Oncology

2009

101

Predictability of the survival of patients with advanced ovarian cancer.

Hans C. van Houwelingen, W.W. ten Bokkel Huinink, M E van der Burg,

Journal of Clinical Oncology

1989

88

Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors.

L. Pronk, Jan H.M. Schellens, A.S.T. Planting,

Journal of Clinical Oncology

1997

66

Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer.

G.J. Creemers, C J Gerrits, Jan H.M. Schellens,

Journal of Clinical Oncology

1996

65

Analysis of cumulative probabilities shows that the efficacy of 5HT3 antagonist prophylaxis is not maintained.

Ronald de Wit, P.I.M. Schmitz, Jaap Verweij,

Journal of Clinical Oncology

1996

49

A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials)

Gordon Rustin, M E van der Burg

Journal of Clinical Oncology

2009

47

CA 125 in ovarian cancer.

M E van der Burg, Frits B. Lammes, Jaap Verweij

PubMed

1992

43

Page 1